Thursday, 15 October 2026European Markets

SEABIRD EXPLORAT Stock Is 16% Up So Far Today

Loading stream...

(VIANEWS) - Shares of SEABIRD EXPLORAT (Oslo Børs Benchmark Index_GI: SBX.OL) jumped by a staggering 16.97% to kr4.14 at 11:37 EST on Friday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is sliding 0.37% to kr1,208.99, following the last session's downward trend. This seems, at the moment, a somewhat down trend exchanging session today.

SEABIRD EXPLORAT's last close was kr3.54, 26.05% below its 52-week high of kr4.78.

About SEABIRD EXPLORAT

SeaBird Exploration Plc, together with its subsidiaries, provides marine 2D and 3D seismic data for the oil and gas industry in Europe, Africa, the Middle East, North and South America, and the Asia Pacific. It offers 2D seismic; and source vessels that provide conventional undershoot, 4D repeat survey, wide azimuth, push reverse, long-term charter and vessel management, in-house source modelling and environmental decay analysis, and spot charter services. The company was founded in 1996 and is based in Nicosia, Cyprus.

Earnings Per Share

As for profitability, SEABIRD EXPLORAT has a trailing twelve months EPS of kr-0.73.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.32%.

Sales Growth

SEABIRD EXPLORAT's sales growth is negative 71.8% for the present quarter and negative 88.1% for the next.

Volatility

SEABIRD EXPLORAT's last week, last month's, and last quarter's current intraday variation average was a negative 0.11%, a negative 0.17%, and a positive 1.85%.

SEABIRD EXPLORAT's highest amplitude of average volatility was 0.90% (last week), 1.77% (last month), and 1.85% (last quarter).

Moving Average

SEABIRD EXPLORAT's value is higher than its 50-day moving average of kr3.80 and higher than its 200-day moving average of kr3.97.

More news about SEABIRD EXPLORAT (SBX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com